You are in: eMedicine Specialties > Emergency Medicine > RHEUMATOLOGY Temporomandibular Joint SyndromeArticle Last Updated: Dec 6, 2006AUTHOR AND EDITOR INFORMATIONAuthor: Joshua Parnes, MD, Staff Physician, Department of Emergency Medicine, Kings County Hospital Center Coauthor(s): Richard Sinert, DO, Associate Professor of Emergency Medicine, Clinical Assistant Professor of Medicine, State University of New York College of Medicine; Consulting Staff, Department of Emergency Medicine, Kings County Hospital Center; Steven Heffer, MD, Consulting Staff, Department of Emergency Medicine, Greenwich Hospital Editors: Jerome FX Naradzay, MD, FACEP, Medical Director, Consulting Staff, Department of Emergency Medicine, Maria Parham Hospital; Medical Examiner, Vance County, North Carolina; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Gino A Farina, MD, Program Director, Associate Professor of Clinical Emergency Medicine, Department of Emergency Medicine, Long Island Jewish Medical Center, Albert Einstein College of Medicine; John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center; Charles V Pollack, Jr, MD, MA, FACEP, Professor, Department of Emergency Medicine, University of Pennsylvania College of Medicine; Chairman, Department of Emergency Medicine, Pennsylvania Hospital Author and Editor Disclosure Synonyms and related keywords: temporomandibular joint dysfunction syndrome, TMJ syndrome, myofascial pain dysfunction syndrome, MPD syndrome, temporal mandibular joint, locked jaw, neck pain, movement of the jaw INTRODUCTIONBackgroundTMJ, or temporal mandibular joint, is the synovial joint that connects the jaw to the skull. These two joints are located just in front of each ear. Each joint is composed of the condyle of the mandible, an articulating disk, and the articular tubercle of the temporal bone. The movements allowed are side to side, up and down, as well as protrusion and retrusion. This complicated joint along with its attached muscles, allows movements needed for speaking, chewing, and making facial expressions. Uyanik et al identifies 3 distinct causes of pain at the TMJ, which collectively fall under the broader term of TMJ syndrome.
PathophysiologyThe pathophysiology is not entirely understood, but it is believed that TMJ dysfunction syndrome arises from both local insults and systemic disorders. Local problems frequently arise from articular disc displacement and hereditary conditions affecting the structures of the joint itself, such as hypoplastic mandibular condyles. The TMJs also can be affected by conditions such as rheumatoid arthritis, osteoarthritis, and diseases of the articular disks. In addition, hypermobile TMJs, nocturnal jaw clenching, nocturnal teeth grinding, jaw clenching due to psychosocial stresses, and local trauma also play a significant role. As described by Hegde et al, a strong understanding of how the trigeminal nerve innervates the TMJ and surrounding structures explains the pain and referred pain patterns of TMJ disorders. Irritation of the mandibular branch (V3) of the trigeminal nerve results in pain locally at the TMJ and also to other areas of V3 sensory innervation, which include the ipsilateral skin, teeth, side of the head, and scalp. FrequencyUnited StatesCurrently, an estimated 10 million people have TMJ disorders, and roughly 25% of the population have symptoms at some point in their lives. Mortality/MorbidityThe morbidity of the disorder is related to significant pain on movement of the jaw. While some patients' symptoms may resolve within weeks, others may have chronic symptoms that persist even with extensive therapy. One study by Rammelsberg et al followed 235 patients over 5 years. In this study, roughly one third of patients had completely resolved pain, one third had continuous pain over the 5 years, and one third had recurrent episodes with periods of remission. RaceNo apparent association with race exists. SexFemale-to-male ratio is roughly 4:1. Age
CLINICALHistory
Physical
DIFFERENTIALSDental, Infections Dislocations, Mandible Fractures, Mandible Gout and Pseudogout Headache, Cluster Headache, Migraine Headache, Tension Myopathies Otitis Media Sinusitis Temporal Arteritis Tick-Borne Diseases, Lyme Trigeminal Neuralgia
|
| Drug Name | Ibuprofen (Motrin, Advil, Ibuprin, Nuprin) |
|---|---|
| Description | Usually DOC for treatment of mild to moderate pain if no contraindications exist; inhibits inflammatory reactions and pain, probably by decreasing activity of enzyme cyclooxygenase, which results in inhibition of prostaglandin synthesis. |
| Adult Dose | 200-400 mg PO q4-6h prn; not to exceed 3.2 g/d |
| Pediatric Dose | <6 months: Not established 6 months to 12 years: 10-70 mg/kg/d PO divided tid/qid; start at lower end of dosing range and titrate upward; not to exceed 2.4 g/d >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency; high risk of bleeding; because of potential cross-sensitivity to other NSAIDs, do not administer to patients with documented hypersensitivity to aspirin, iodides, or other NSAIDs |
| Interactions | Probenecid may increase concentrations and possibly toxicity of NSAIDs; ibuprofen may decrease effect of loop diuretics when coadministered; PT may increase when ibuprofen is coadministered with anticoagulants; monitor PT and bleeding closely; ibuprofen and other NSAIDs may increase serum lithium levels and risk of methotrexate toxicity |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Category D in third trimester of pregnancy; acute renal insufficiency, hyperkalemia, hyponatremia, interstitial nephritis, and renal papillary necrosis may occur; increases risk of acute renal failure in patients with preexisting renal disease or compromised renal perfusion; caution in congestive heart failure, hypertension, and decreased hepatic function; caution in anticoagulation abnormalities or during anticoagulant therapy; severe GI tract ulceration and bleeding can occur; monitor patients closely when administering prolonged treatments; NSAIDs can inhibit platelet aggregation, but at a lower degree than that observed with aspirin; low WBC counts can occur but usually return to normal as therapy continues; discontinuation of therapy may be necessary if persistent leukopenia, granulocytopenia, or thrombocytopenia is present |
| Drug Name | Naproxen (Aleve, Anaprox, Naprosyn) |
|---|---|
| Description | Used for relief of mild to moderate pain; inhibits inflammatory reactions and pain by decreasing activity of enzyme cyclooxygenase, which results in decrease of prostaglandin synthesis. |
| Adult Dose | 250-500 mg PO bid; not to exceed 1.25 g/d; may increase to 1.5 g/d for limited periods |
| Pediatric Dose | <2 years: Not established >2 years: 2.5 mg/kg/dose PO; not to exceed 10 mg/kg/d |
| Contraindications | Documented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency; high risk of bleeding |
| Interactions | Probenecid and lithium may increase concentrations and possibly toxicity of NSAIDs; effect of loop diuretics may decrease with coadministration; PT may increase with coadministration of anticoagulants; monitor PT and bleeding; coadministration with phenytoin may increase serum phenytoin levels, resulting in an increase in pharmacologic and toxic effects of phenytoin |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Category D in third trimester of pregnancy; acute renal insufficiency, hyperkalemia, hyponatremia, interstitial nephritis, and renal papillary necrosis may occur; increases risk of acute renal failure in patients with preexisting renal disease or compromised renal perfusion; caution in congestive heart failure, hypertension, and decreased hepatic function; caution in anticoagulation abnormalities or during anticoagulant therapy; severe GI tract ulceration and bleeding can occur; monitor patients closely when administering prolonged treatments; NSAIDs can inhibit platelet aggregation, but at a lower degree than that observed with aspirin; low WBC counts can occur but usually return to normal as therapy continues; discontinuation of therapy may be necessary if persistent leukopenia, granulocytopenia, or thrombocytopenia is present |
| Drug Name | Flurbiprofen (Ansaid) |
|---|---|
| Description | Analgesic, antipyretic, and anti-inflammatory effects; may inhibit cyclooxygenase enzyme, causing inhibition of prostaglandin biosynthesis that in turn may result in analgesic and anti-inflammatory activities. |
| Adult Dose | 200-300 mg/d PO divided bid/qid |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; epithelial herpes simplex keratitis |
| Interactions | Probenecid and lithium may increase concentrations and possibly toxicity of NSAIDs; effect of loop diuretics may decrease with coadministration; coadministration with anticoagulants may prolong PT; monitor PT and bleeding; nephrotoxicity of both cyclosporine and flurbiprofen may be increased; coadministration with phenytoin may increase serum phenytoin levels, resulting in increase in pharmacologic and toxic effects of phenytoin |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Category D in third trimester of pregnancy; acute renal insufficiency, hyperkalemia, hyponatremia, interstitial nephritis, and renal papillary necrosis may occur; increases risk of acute renal failure in patients with preexisting renal disease or compromised renal perfusion; caution in congestive heart failure, hypertension, and decreased hepatic function; caution in anticoagulation abnormalities or during anticoagulant therapy; severe GI tract ulceration and bleeding can occur; monitor patients closely when administering prolonged treatments; NSAIDs can inhibit platelet aggregation, but at a lower degree than that observed with aspirin; low WBC counts can occur but usually return to normal as therapy continues; discontinuation of therapy may be necessary if persistent leukopenia, granulocytopenia, or thrombocytopenia is present |
| Drug Name | Ketoprofen (Oruvail, Orudis, Actron) |
|---|---|
| Description | Used for relief of mild to moderate pain and inflammation; administer small dosages initially to patients with small bodies, older persons, and those with renal or liver disease; doses >75 mg do not increase therapeutic effects; administer high doses with caution and closely observe patient for response. |
| Adult Dose | 25-50 mg PO q6-8h prn; not to exceed 300 mg/d |
| Pediatric Dose | <3 months: Not established 3 months to 12 years: 0.1-1 mg/kg PO q6-8h >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; GI disease; cardiovascular disease; renal or hepatic impairment; patients receiving anticoagulants |
| Interactions | Probenecid and lithium may increase concentrations and possibly toxicity of NSAIDs; effect of loop diuretics may decrease with coadministration; PT may increase when ketoprofen is coadministered with anticoagulants; monitor for bleeding; coadministration with phenytoin may increase serum phenytoin levels, resulting in increase in pharmacologic and toxic effects of phenytoin |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Category D in third trimester of pregnancy; acute renal insufficiency, hyperkalemia, hyponatremia, interstitial nephritis, and renal papillary necrosis may occur; increases risk of acute renal failure in patients with preexisting renal disease or compromised renal perfusion; caution in congestive heart failure, hypertension, and decreased hepatic function; caution in anticoagulation abnormalities or during anticoagulant therapy; severe GI tract ulceration and bleeding can occur; monitor patients closely when administering prolonged treatments; NSAIDs can inhibit platelet aggregation, but at a lower degree than that observed with aspirin; low WBC counts can occur but usually return to normal as therapy continues; discontinuation of therapy may be necessary if persistent leukopenia, granulocytopenia, or thrombocytopenia is present |
| Drug Name | Mefenamic acid (Ponstel) |
|---|---|
| Description | Inhibits inflammatory reactions and pain by decreasing prostaglandin synthesis. |
| Adult Dose | 500 mg PO initially followed by 250 mg q4h prn |
| Pediatric Dose | <12 years: Not established >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency; high risk of bleeding |
| Interactions | Coadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and possibly toxicity of NSAIDs; may decrease effects of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT when taking anticoagulants (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Category D in third trimester of pregnancy; may have adverse effects in fetus; caution in congestive heart failure, hypertension, and decreased renal and hepatic function; caution in anticoagulation abnormalities or during anticoagulant therapy |
| Drug Name | Indomethacin (Indocin, Indochron E-R) |
|---|---|
| Description | Rapidly absorbed; metabolism occurs in liver by demethylation, deacetylation, and glucuronide conjugation; inhibits prostaglandin synthesis. |
| Adult Dose | 25-50 mg PO bid/tid 75 mg SR PO bid; not to exceed 200 mg/d |
| Pediatric Dose | 1-2 mg/kg/d divided PO bid/qid; not to exceed 4 mg/kg/d or 150-200 mg/d |
| Contraindications | Documented hypersensitivity; GI bleeding or renal insufficiency |
| Interactions | Coadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and possibly toxicity of NSAIDs; may decrease effects of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT when taking anticoagulants (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Category D in third trimester of pregnancy; acute renal insufficiency, hyperkalemia, hyponatremia, interstitial nephritis, and renal papillary necrosis may occur; increases risk of acute renal failure in patients with preexisting renal disease or compromised renal perfusion; reversible leukopenia may occur (discontinue if persistent leukopenia, granulocytopenia, or thrombocytopenia) |
| Drug Name | Piroxicam (Feldene) |
|---|---|
| Description | Decreases activity of cyclooxygenase, which in turn inhibits prostaglandin synthesis; effects decrease formation of inflammatory mediators. |
| Adult Dose | 10-20 mg/d PO qd |
| Pediatric Dose | 0.2-0.3 mg/kg/d PO qd; not to exceed 15 mg/d |
| Contraindications | Documented hypersensitivity; active GI bleeding |
| Interactions | Coadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and possibly toxicity of NSAIDs; may decrease effects of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT when taking anticoagulants (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Category D in third trimester of pregnancy; acute renal insufficiency, hyperkalemia, hyponatremia, interstitial nephritis, and renal papillary necrosis may occur; increases risk of acute renal failure in patients with preexisting renal disease or compromised renal perfusion; reversible leukopenia may occur (discontinue if persistent leukopenia, granulocytopenia, or thrombocytopenia) |
Used for muscle relaxant properties but relatively contraindicated in pediatric patients because of sedating properties; appear to potentiate effects of GABA and facilitate inhibitory GABA neurotransmission and other inhibitory transmitters by binding to specific receptor sites.
| Drug Name | Diazepam (Valium) |
|---|---|
| Description | Depresses all levels of CNS, including limbic and reticular formation, possibly by increasing activity of GABA, a major inhibitory neurotransmitter. Individualize dosage and increase cautiously to avoid adverse effects. |
| Adult Dose | 2-10 mg PO bid/qid |
| Pediatric Dose | 0.05-0.3 mg/kg/dose PO over 2-3 min q15-30min; not to exceed 10 mg; repeat in 2-4 h prn |
| Contraindications | Documented hypersensitivity; narrow-angle glaucoma; first trimester of pregnancy |
| Interactions | Toxicity of benzodiazepines in CNS is increased when used concurrently with alcohols, phenothiazines, barbiturates, and MAOIs; cisapride significantly can increase diazepam levels |
| Pregnancy | D - Unsafe in pregnancy |
| Precautions | Caution in patients receiving other CNS depressants; caution in patients diagnosed with low albumin levels or hepatic failure since diazepam toxicity may increase |
Temporomandibular Joint Syndrome excerpt
Article Last Updated: Dec 6, 2006